Oral composition

Abstract

An object of the present invention is to provide an oral composition excellent in stability of a cationic bactericide after storage and in kneaded skin after storage.SOLUTION: The present invention provides an oral composition comprising a cationic bactericide (component (A)), a nonionic surfactant (component (B)), and a fluorine-containing compound (component (C)), wherein the content of the component (C) is 3000 to 20000 ppm in terms of a fluoride ion concentration, and the ratio (C) / (B) of the fluoride ion concentration corresponding to the content of the component (C) to the content of the component (B) is 2000 to 50000.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to an oral composition. [Background technology]

[0002] It is known that the use of cationic bactericides such as quaternary ammonium salts is effective in preventing periodontal disease and dental caries. Furthermore, oral compositions contain oil-soluble ingredients such as flavorings, and nonionic surfactants are commonly used as solubilizers.

[0003] For example, Patent Documents 1 to 4 describe dentifrice compositions containing a quaternary ammonium salt such as cetylpyridium chloride and a nonionic surfactant such as coconut oil fatty acid amidopropyl betaine. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Laid-Open No. 2013-067568 [Patent Document 2] Special Publication No. 2011-513436 [Patent Document 3] Japanese Patent Application Laid-Open No. 2007-084471 [Patent Document 4] Japanese Patent Application Laid-Open No. 2002-255771 Summary of the Invention [Problem to be solved by the invention]

[0005] However, cationic disinfectants such as quaternary ammonium salts have poor storage stability over time (especially at high temperatures) when used in compositions containing nonionic surfactants. Ensuring storage stability over time in compositions containing cationic disinfectants and nonionic surfactants is an issue.

[0006] The present invention aims to provide an oral composition that is excellent in the stability of the cationic bactericide after storage and in the smoothness of the skin after storage, by adding a fluorine-containing compound in an amount of 3,000 to 20,000 ppm, calculated as a fluoride ion concentration, to a dentifrice composition that contains a cationic bactericide and a nonionic surfactant. [Means for solving the problem]

[0007] The present invention provides the following [1] to

[11] . [1] An oral composition comprising component (A): a cationic bactericide, component (B): a nonionic surfactant, and component (C): a fluorine-containing compound, wherein the content of component (C) is in an amount equivalent to a fluoride ion concentration of 3,000 to 20,000 ppm, and the ratio (C) / (B) of the fluoride ion concentration corresponding to the content of component (C) to the content of component (B) is 2,000 to 50,000. [2] The oral composition according to [1], wherein component (A) is one or more selected from the group consisting of chlorhexidine hydrochloride, cetylpyridinium chloride, benzalkonium chloride, and benzethonium chloride. [3] The oral composition according to [1] or [2], wherein component (B) is one or more selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, and alkyl glucoside. [4] The oral composition according to any one of [1] to [3], wherein the content of component (B) is 0.05 to 10.0% by mass. [5] The oral composition according to [3], wherein component (B) contains polyoxyethylene hydrogenated castor oil in an amount of 0.05 to 10% by mass relative to the total amount of the composition. [6] The oral composition according to [3] or [5], wherein component (B) contains a polyoxyethylene sorbitan fatty acid ester in an amount of 0.05 to 10% by mass relative to the total amount of the composition. [7] The oral composition according to any one of [3], [5], and [6], wherein component (B) contains an alkyl glucoside in an amount of 0.05 to 10% by mass relative to the total amount of the composition. [8] The oral composition according to any one of [1] to [7], which is a dentifrice composition. [9] The oral composition according to any one of [1] to [8], which is for treating or preventing periodontal disease.

[10] The oral composition according to any one of [1] to [8], which is an external preparation composition.

[11] An agent for treating or preventing periodontal disease, comprising component (A): a cationic bactericide, component (B): a nonionic surfactant, and component (C): a fluorine-containing compound, wherein the content of component (C) is in an amount that, when converted into a fluoride ion concentration, is 3,000 to 20,000 ppm, and the ratio (C) / (B) of the fluoride ion concentration corresponding to the content of component (C) to the content of component (B) is 2,000 to 50,000. [Effects of the Invention]

[0008] According to the present invention, it is possible to provide an oral composition which has excellent stability of the cationic bactericide after storage and excellent surface smoothness after storage. DETAILED DESCRIPTION OF THE INVENTION

[0009] [1. Oral composition] The oral composition of the present invention contains the following components (A) to (C).

[0010] [Component (A)] Component (A) is preferably a cationic bactericide. By including component (A), a bactericidal effect on oral bacteria can be exerted.

[0011] A cationic disinfectant can be used as component (A). Examples of the cationic disinfectant include quaternary ammonium salts and biguanide disinfectants, with quaternary ammonium salts being preferred. Examples of the quaternary ammonium salts include alkylpyridinium salts, benzyl long-chain alkyl short-chain dialkylammonium salts, and long-chain alkyl short-chain trialkylammonium salts. Examples of the biguanide disinfectant include chlorhexidine salts. Among these, one or more selected from cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, and chlorhexidine hydrochloride are preferred.

[0012] The content of component (A) is preferably 0.0005% by mass or more, or 0.001% by mass or more, more preferably 0.005% by mass or more, or 0.01% by mass or more, based on the total composition. This allows the oral composition to exhibit a better bactericidal effect. The upper limit is preferably 0.1% by mass or less, more preferably 0.05% by mass or less. This allows the oral composition to have a better smooth surface. Therefore, the content of component (A) is preferably 0.0005 to 0.1% by mass or 0.001 to 0.05% by mass, or more preferably 0.005 to 0.05% by mass or 0.01 to 0.05% by mass, based on the total composition.

[0013] [Component (B)] Component (B) is a nonionic surfactant. By including component (B), it is possible to exert a bactericidal effect on oral bacteria.

[0014] As the nonionic surfactant, various known surfactants can be used, for example, sugar alcohol fatty acid esters such as polyoxyethylene hydrogenated castor oil, polyoxyethylene fatty acid esters, sucrose fatty acid esters, maltose fatty acid esters, maltitol fatty acid esters, and lactol fatty acid esters, alkylolamides, alkyl glucosides, polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyoxyethylene glycol fatty acid esters, polyethylene glycol fatty acid esters, polyoxyethylene polyoxypropylene glycol, fatty acid diethanolamides such as lauric acid mono- or diethanolamide, polyoxyethylene alkyl ethers, and polyoxyethylene alkylphenyl ethers. Among these, one or more selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, and alkyl glucoside are preferred.

[0015] The polyoxyethylene sorbitan fatty acid ester is preferably a polyoxyethylene sorbitan fatty acid ester derived from a fatty acid having 10 to 22 carbon atoms, more preferably a polyoxyethylene sorbitan fatty acid ester derived from a fatty acid having 14 to 20 carbon atoms. Of these, polyoxyethylene sorbitan monostearate fatty acid ester is preferred. The average number of moles of EO added in the polyoxyethylene sorbitan fatty acid ester is preferably 5 to 30 moles, more preferably 10 to 25 moles.

[0016] The alkyl glycoside is preferably an alkyl polyglycoside having 8 to 20 carbon atoms in the alkyl group portion, and more preferably an alkyl polyglycoside having 10 to 28 carbon atoms in the alkyl group portion.

[0017] The content of component (B) is preferably 0.05% by mass or more, or 0.1% by mass or more, more preferably 0.25% by mass or more, based on the total mass of the composition. This allows the oral composition to have a better smooth surface. The upper limit is preferably 10% by mass or less, or 8% by mass or less, more preferably 5% by mass or less. This allows the oral composition to exhibit a better bactericidal effect. Therefore, the content of component (B) is preferably 0.05 to 10% by mass, or 0.1 to 8% by mass, more preferably 0.25 to 5% by mass, based on the total mass of the composition.

[0018] When polyoxyethylene hydrogenated castor oil is used as component (B), its content is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, based on the total mass of the composition. The upper limit is preferably 10% by mass or less, more preferably 5% by mass or less, or 2% by mass or less. Therefore, the content of polyoxyethylene hydrogenated castor oil is preferably 0.05 to 10% by mass, more preferably 0.1 to 5% by mass, or 0.1 to 2% by mass, based on the total mass of the composition. When the content of polyoxyethylene hydrogenated castor oil satisfies the above numerical range, the effects of the present invention can be more suitably exhibited.

[0019] When a polyoxyethylene sorbitan fatty acid ester is used as component (B), its content is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, based on the total mass of the composition. The upper limit is preferably 10% by mass or less, more preferably 8% by mass or less. Therefore, the content of the polyoxyethylene sorbitan fatty acid ester is preferably 0.05 to 10% by mass, more preferably 0.1 to 8% by mass, based on the total mass of the composition. When the content of the polyoxyethylene sorbitan fatty acid ester satisfies the above numerical range, the effects of the present invention can be more suitably exhibited.

[0020] When an alkyl glucoside is used as component (B), its content is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, based on the total mass of the composition. The upper limit is preferably 10% by mass or less, more preferably 8% by mass or less. Therefore, the content of the alkyl glucoside is preferably 0.05 to 10% by mass, more preferably 0.1 to 8% by mass, based on the total mass of the composition. When the content of the alkyl glucoside satisfies the above numerical range, the effects of the present invention can be more suitably exhibited.

[0021] [Component (C)] Component (C) is a fluorine-containing compound. By including component (C), the oral composition can exhibit good bactericidal stability.

[0022] Examples of fluorine-containing compounds include alkali metal fluorides, metal fluorides, monofluorophosphates, and salts thereof. Among these, one or more compounds selected from sodium fluoride, sodium monofluorophosphate, and stannous fluoride are preferred, and one or more compounds selected from sodium fluoride and sodium monofluorophosphate are more preferred.

[0023] The content of component (C) is preferably 3000 ppm or more, more preferably 4000 ppm or more, calculated as a fluoride ion concentration relative to the total composition. This allows the oral composition to exhibit good bactericidal stabilization effects. The upper limit is preferably 20000 ppm or less, more preferably 15000 ppm or less. This allows the oral composition to have a good smooth surface. Therefore, the content of component (C) is preferably 3000 to 20000 ppm, more preferably 4000 to 15000 ppm, calculated as a fluoride ion concentration relative to the total composition.

[0024] The suitable content of component (C) varies depending on the selected fluorine-containing compound. Specifically, for example, when component (C) is sodium fluoride, it is preferably 0.6% by mass or more, more preferably 0.8% by mass or more, based on the total amount of the composition. The upper limit is preferably 4.5% by mass or less, more preferably 3.4% by mass or less. Therefore, it is preferably 0.6 to 4.5% by mass, more preferably 0.8 to 3.4% by mass.

[0025] Furthermore, for example, when component (C) is sodium monofluorophosphate, the content of sodium monofluorophosphate is preferably 2.2% by mass or more, more preferably 3.0% by mass or more, based on the total amount of the composition. The upper limit is preferably 15.2% by mass or less, more preferably 11.4% by mass or less. Therefore, it is preferably 2.2 to 15.2% by mass, more preferably 3.0 to 11.4% by mass.

[0026] Furthermore, for example, when component (C) is stannous fluoride, the content of stannous fluoride is preferably 1.2 mass% or more, more preferably 1.6 mass% or more, based on the total amount of the composition. The upper limit is preferably 8.3 mass% or less, more preferably 6.2 mass% or less. Therefore, it is preferably 1.2 to 8.3 mass%, more preferably 1.6 to 6.2 mass%.

[0027] When the content (% by mass) of each component (C) satisfies the above-mentioned numerical range, the content (ppm) of component (C) converted into fluorine ion concentration satisfies the above-mentioned numerical range, and the effects of the present invention can be more suitably exhibited.

[0028] [(C) / (B)] The ratio (C) / (B) is the ratio of the fluoride ion concentration (ppm) corresponding to the content of component (C) in the composition to the content (% by mass) of component (B). (C) / (B) is preferably 2000 or more, or 2100 or more, more preferably 3000 or more, or 3200 or more. This allows the oral composition to exhibit good bactericidal stabilization effect. The upper limit is preferably 50,000 or less, or 49,800 or less, more preferably 30,000 or less, or 10,000 or less. This allows the oral composition to be applied smoothly to the skin. Therefore, (C) / (B) is preferably 2000 to 50,000, or 2100 to 49,800, more preferably 3000 to 30,000, or 3200 to 10,000.

[0029] [Optional ingredients] The oral composition may contain optional ingredients other than the above ingredients (A) to (C) depending on the intended use, dosage form, etc., as long as the ingredients do not impair the effects of the present invention. Specifically, surfactants, abrasives, binders, humectants, and, if necessary, pH adjusters, sweeteners, preservatives, colorants, flavorings, various medicinal ingredients, oily ingredients, etc. may be added.

[0030] -Surfactants- As the surfactant, surfactants other than the above-mentioned component (B), that is, at least one selected from anionic surfactants and zwitterionic surfactants, can be used.

[0031] (anionic surfactants) Examples of anionic surfactants include alkyl sulfates, α-olefin sulfonates, N-acylsulfonates, sulfates of glycerin fatty acid esters, acylamino acids, and acyltaurines. The alkyl and acyl groups may be linear or branched, saturated or unsaturated, and typically contain 10 to 20 carbon atoms, preferably 12 to 18, and more preferably 12 to 14 carbon atoms. The salts may be selected from pharmacologically acceptable salts. Examples of pharmacologically acceptable salts include base addition salts and amino acid salts. Specific examples include inorganic base salts such as sodium salts, potassium salts, calcium salts, magnesium salts, and ammonium salts; organic base salts such as triethylammonium salts, triethanolammonium salts, pyridinium salts, and diisopropylammonium salts; and basic amino acid salts such as arginine salts.

[0032] Examples of alkyl sulfates include lauryl sulfate and myristoyl sulfate. Examples of α-olefin sulfonates include α-olefin sulfonates having 12 to 18 carbon atoms, such as tetradecene sulfonate.

[0033] Examples of acyl amino acids include lauroyl sarcosine salts and lauroyl glutamate salts, and examples of acyltaurines include lauroyl methyl taurine salts.

[0034] Other examples of anionic surfactants include hydrogenated coconut fatty acid monoglyceride sodium monosulfate and sodium lauryl sulfoacetate.

[0035] (zwitterionic surfactants) Examples of zwitterionic surfactants include N-alkyldiaminoethylglycines such as N-lauryldiaminoethylglycine and N-myristyldiaminoethylglycine; betaine-type amphoteric surfactants such as N-alkyl N-carboxymethylammonium betaine, 2-alkyl-1-hydroxyethylimidazoline betaine sodium, alkyldimethylaminoacetic acid betaine (e.g., lauryldimethylaminoacetic acid betaine), and fatty acid amidopropyldimethylaminoacetic acid betaine (e.g., cocamidopropyl betaine); imidazoline-type amphoteric surfactants such as N-fatty acid acyl-N-carboxymethyl-N-hydroxyethylethylenediamine salts (e.g., N-coconut oil fatty acid acyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine), coconut oil fatty acid imidazolinium betaine, and 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine; and alkyl betaines such as lauryldimethylaminoacetic acid betaine.

[0036] The amount of these surfactants added is usually 0.001 to 10% by mass, preferably 0.1 to 5% by mass, and more preferably 0.5 to 3% by mass, based on the total amount of the composition.

[0037] -Abrasives- The abrasive may be either inorganic or organic. Examples of inorganic abrasives include silica-based abrasives such as precipitated silica, crystalline silica, amorphous silica, silica gel, aluminosilicate, zirconosilicate, and titanium-bonded silica; zeolites; calcium phosphate compounds such as anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, calcium pyrophosphate, dibasic calcium phosphate dihydrate or anhydrous, monobasic calcium phosphate, tribasic calcium phosphate, and tetrabasic calcium phosphate; calcium carbonate-based abrasives such as calcium carbonate; aluminum hydroxide, alumina, magnesium carbonate, tribasic magnesium phosphate, calcium sulfate, bentonite, zirconium silicate, and hydroxyapatite. Examples of organic abrasives include synthetic resin-based abrasives. The amount of the abrasive to be added is preferably 7% by mass or more, more preferably 10% by mass or more, and preferably 50% by mass or less, more preferably 30% by mass or less, and is preferably 7 to 50% by mass, and more preferably 10 to 30% by mass, based on the total amount of the composition.

[0038] -Binder- Examples of binders include polysaccharide thickeners (e.g., xanthan gum, guar gum, gellan gum, tragacanth gum, karaya gum, gum arabic, locust bean gum, carrageenan, sodium alginate), cellulose binders (e.g., carboxymethyl cellulose (CMC), hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, cationized cellulose, etc., and pharmacologically acceptable salts thereof, such as sodium salts), and synthetic water-soluble polymers (e.g., sodium polyacrylate, carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, propylene glycol alginate). Furthermore, inorganic binders such as thickening silica and aluminum silicate can also be added.

[0039] -Wetting agent- As the humectant, sugar alcohols and polyhydric alcohols other than sugar alcohols are preferred. Examples of sugar alcohols include sugar alcohols such as sorbitol (sorbite), xylitol (xylitol), erythritol, maltitol, lactitol, and reduced starch saccharification products; and polyhydric alcohols such as glycerin, ethylene glycol, propylene glycol, dipropylene glycol, butylene glycol, and polyethylene glycol. Examples of polyethylene glycols include polyethylene glycols with an average molecular weight of 150 to 6000, and preferably polyethylene glycols with an average molecular weight of 190 to 630. Specific examples include PEG200, PEG300, PEG400, and PEG600. The content of the humectant is typically 1 to 70% by mass, preferably 1 to 65% by mass, more preferably 1 to 60% by mass, even more preferably 3 to 60% by mass, and even more preferably 3 to 30% by mass, relative to the total amount of the oral composition.

[0040] - pH adjuster - Examples of pH adjusters include organic acids such as phthalic acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid, and lactic acid, or their salts (e.g., sodium citrate), inorganic acids such as phosphoric acid (e.g., orthophosphoric acid), or their salts (e.g., potassium salts, sodium salts, and ammonium salts), and hydroxides such as sodium hydroxide and potassium hydroxide. Examples of inorganic acid salts include disodium hydrogen phosphate and sodium dihydrogen phosphate. The content of the pH adjuster can usually be set to an amount that will give the oral composition a pH of 5.0 to 9.0 after addition, and preferably an amount that will give the oral composition a pH of 6.0 to 8.5.

[0041] In this specification, the pH value generally refers to the value measured 3 minutes after the start of measurement at 25° C. The pH value can be measured, for example, using a pH meter (model number Hm-30S) manufactured by Toa Dempa Kogyo Co., Ltd.

[0042] -Sweetener- Examples of sweeteners include saccharin, saccharin sodium, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidin dihydrochalcone, perillartine, thaumatin, and aspartyl phenylalanine methyl ester.

[0043] -Preservatives- Examples of preservatives include benzoates such as sodium benzoate, and parahydroxybenzoic acid esters such as methyl parahydroxybenzoate, ethyl parahydroxybenzoate, and butyl parahydroxybenzoate. One type of preservative may be used alone, or two or more types may be used in combination.

[0044] -Coloring agent- Examples of colorants include natural colorants such as safflower red, gardenia yellow, gardenia blue, perilla color, red koji color, red cabbage color, carrot color, hibiscus color, cacao color, spirulina blue, and tamarind color, as well as legally designated colorants such as Red No. 2, Red No. 3, Red No. 104, Red No. 105, Red No. 106, Red No. 227, Yellow No. 4, Yellow No. 5, Green No. 3, and Blue No. 1, riboflavin, sodium copper chlorophine, and titanium dioxide. When the oral composition contains a colorant, the content thereof is preferably 0.00001 to 3% by mass of the total amount of the composition.

[0045] Examples of fragrances include peppermint oil, spearmint oil, Japanese peppermint oil, anise oil, cassia oil, eucalyptus oil, wintergreen oil, mastic oil, neroli oil (orange flower oil), lemongrass oil, jasmine oil, rose oil, iris oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, laurel oil, chamomile oil, coriander oil, caraway oil, basil oil, marjoram oil, lemon oil, orange oil, lime oil, mandarin oil, grapefruit oil, yuzu oil, nutmeg oil, lavender oil, paracles oil, vanilla oil, cinnamon oil, pimento oil, cinnamon leaf oil, Natural essential oils such as perilla oil and wintergreen oil; fragrance components contained in the above natural essential oils such as menthol, carvone, cinnamic aldehyde, p-methoxycinnamic aldehyde, anethole, 1,8-cineole, methyl salicylate, eugenol, thymol, linalool, linalool oxide, limonene, menthone, menthyl acetate, citral, decanal, camphor, borneol, pinene, spilanthol, n-decyl alcohol, citronellol, α-terpineol, citronellyl acetate, ethyl linalool, methyl jasmonate, and vanillin;Ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, cis-3-hexenol, trans-2-hexenol, hexyl acetate, ethyl 2-methylbutyrate, benzyl alcohol, linalyl acetate, phenylethyl glycidate, phenylethyl alcohol, allyl hexanoate, octanol, methyl cinnamate, methylheptyne carbonate, ionone, ethyl-β-methylthiopropionate, cis-6-nonenol, methyl anthranilate, ethyl methylphenylglycidate, benzaldehyde, ethyl vanillin, vanillyl butyl ether, furaneol, undecal Flavoring ingredients such as lactone, decalactone, ethyl cyclopentenolone, 3-hydroxy-4,5-dimethylfuran-2-one, cyclotene, 2-methylbutyric acid, acetic acid, propionic acid, menthofuran, maltol, ethyl maltol, N-ethyl-p-menthane-3-carboxamide (N-ethyl-2-isopropyl-5-methylcyclohexanecarboxamide), 7-methyl-3,5-dihydro-2H-benzodioxepin-3-one, menthyl lactate, ethylene glycol-l-menthyl carbonate, etc.; plant extracts such as chili pepper extract, ginger extract, pepper extract, and Japanese pepper extract;and various blended flavors such as mint, fruit, and herb flavors that are made by combining several flavoring ingredients and natural essential oils.Fragrances that can also function as cooling agents include, for example, N-ethyl-p-menthane-3-carboxamide (N-ethyl-2-isopropyl-5-methylcyclohexanecarboxamide), menthyl lactate, menthyl monosuccinate, isopulegol, menthone glycerol ketal, N-(4-cyanomethylphenyl)-p-menthanecarboxamide, 3-l-menthoxypropane-1,2-diol, 5-methyl-2-propan-2-yl-N-(2-pyridin-2-ylethyl)cyclohexane-1-carboxamide, 3-(p-menthane-3carboxamide)ethyl acetate, 2- Other examples include isopropyl-N,2,3-trimethylbutyramide, N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide, Np-benzeneacetatonitrilementhanecarboxamide, N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide, N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5,5-dimethylcyclohexane-1-carboxamide, 2-(4-methylphenoxy)-N-(1H-pyrazol-yl)-N-(thiophen-2-ylmethyl)acetamide, menthyl glyceryl ether, and menthyl succinate. As the fragrance, the above-exemplified fragrances may be used alone or in combination of two or more. When the oral composition contains a flavor, the content thereof is usually 0.000001 to 1% by mass, and preferably 0.01 to 1% by mass, based on the total amount of the composition. When the oral composition contains a flavor that can also function as a cooling agent, the content thereof is preferably 0.00001 to 0.01% by mass, based on the total amount of the composition.

[0046] -Medicinal ingredients- As the medicinal ingredient, ingredients other than the above-mentioned ingredient (A) and ingredient (C) can be used, for example, bactericidal or antibacterial agents such as lysozyme chloride, triclosan, isopropylmethylphenol, zinc gluconate, zinc citrate, etc.; anti-tartar agents such as zeolite, ethanehydroxydiphosphonate, polyphosphates, etc.; anti-inflammatory agents such as tranexamic acid, glycyrrhizic acid or a salt thereof (e.g., dipotassium glycyrrhizinate), glycyrrhetinic acid or a salt thereof (e.g., stearyl glycyrrhetinate), allantoin, allantoin chlorohydroxyaluminum, ε-aminocaproic acid, azulene, etc.; dextranase, Examples of the medicinal ingredients include enzymes such as amylase, protease, mutanase, and lysozyme chloride; vitamins such as vitamin C (e.g., ascorbic acid), vitamin E (e.g., tocopherol acetate, tocopherol nicotinate, tocopherol), and pyridoxine; blood circulation promoters such as vitamin E; astringents such as sodium chloride, alum, and lysozyme chloride; hypersensitivity inhibitors such as potassium nitrate, aluminum lactate, and strontium chloride; cell activators such as sodium chloride and vitamins; water-soluble copper compounds such as copper chlorophyll and copper gluconate; amino acids such as alanine, glycine, and proline; and peptides such as callopeptides. When the oral composition contains a medicinal ingredient, the content thereof can be within a range that does not interfere with the effects of the present invention (a pharmaceutically acceptable range).

[0047] -Oil-based ingredients- Examples of oily components include hydrocarbons such as squalane, (light) liquid paraffin, petrolatum, and microcrystalline wax; higher alcohols (e.g., alcohols having 8 to 22 carbon atoms such as lauryl alcohol, cetyl alcohol, cetostearyl alcohol, oleyl alcohol, and isostearyl alcohol); higher fatty acids (e.g., fatty acids having 8 to 22 carbon atoms such as lauric acid, myristic acid, oleic acid, and isostearic acid), vegetable oils such as olive oil, castor oil, and coconut oil; and fatty acid esters such as isopropyl myristate.

[0048] -Other optional ingredients- The oral composition of the present embodiment may contain any suitable amount of optional components other than those described above.

[0049] In this embodiment, examples of other optional components that may be contained in the oral composition include inorganic compounds such as titanium mica, titanium oxide, zinc oxide, magnesium oxide, and zirconium oxide; natural polymer compounds such as agar, gelatin, starch, and glucomannan; synthetic polymer compounds or copolymers thereof such as polyvinyl acetate, acrylic resin, polyurethane, polyester, polyvinyl chloride, nylon powder, and polyethylene powder; waxes such as carnauba wax, rosin, rice wax, microcrystalline wax, beeswax, and paraffin wax; higher alcohols such as cetanol and stearyl alcohol; polyisobutylene, polybutadiene, urethane, silicone, and natural rubber. The content of these other optional components can be appropriately set within a range that does not interfere with the effects of the present invention.

[0050] [2. Dosage Form] The oral composition of the present invention can be administered, for example, orally (e.g., internally), sublingually, or parenterally (e.g., transdermal mucosal administration, subcutaneous administration). Of these, oral administration and transdermal mucosal administration (external application) are preferred because they are less invasive, with oral administration and oral mucosal administration being more preferred, and oral preparations and external preparations (e.g., external gingival preparations) being even more preferred.

[0051] [3. Uses and dosage forms of oral compositions] The dosage form of the oral composition can be appropriately selected depending on the application form and is not particularly limited. Examples include liquids (liquids such as solutions, emulsions, suspensions, syrups, etc.), semi-solids (gels, creams, pastes, etc.), and solids (tablets, particulates, capsules, films, kneaded materials, molten solids, waxy solids, elastic solids, soft capsules, etc.). Among these, semi-solid forms are preferred. The oral composition of the present invention can be used in solid dosage forms such as lozenges, gummies, chewing gum, and dentifrices. Its semisolid dosage forms can be used in toothpaste, gel dentifrices, and liniments. Its liquid dosage forms can be used in mouthwashes, liquid dentifrices (liquid dentifrices), and mouth fresheners (sprays, etc.). Among these, dentifrices are preferred. As dentifrices, toothpaste and gel dentifrices are preferred.

[0052] -External application composition- The oral composition of the present invention can also be used as an external preparation composition. The dosage form of the external preparation composition can be, for example, a liquid (a liquid such as a solution, emulsion, suspension, or syrup) or a semi-solid (a gel, cream, or paste), with a semi-solid being preferred.

[0053] The topical composition can be prepared as a liniment, preferably as an ointment. The production method is not particularly limited, and a conventional method can be used depending on the dosage form. The topical composition is usually applied to the oral cavity, preferably the oral mucosa, gingiva, and gums.

[0054] -Oral composition for treating or preventing periodontal disease, and agent for treating or preventing periodontal disease- The oral composition of the present invention has an excellent antibacterial effect and is therefore useful for the treatment or prevention of periodontal disease (e.g., treatment, improvement, and alleviation of symptoms of periodontal disease) and can be used as a therapeutic or preventive agent for periodontal disease. Furthermore, alveolar pyorrhea is a type of periodontal disease. Therefore, the oral composition of the present invention is useful for the treatment or prevention of alveolar pyorrhea and can be used as a therapeutic or preventive agent for periodontal disease.

[0055] [4. Manufacturing Method and Properties of Oral Compositions] The method for producing the oral composition is not particularly limited, and it can be prepared by any conventional method depending on the dosage form. For example, when used as a toothpaste, a method can be used in which the components soluble in a solvent are prepared, and then the other insoluble components are mixed, and degassing (e.g., reduced pressure, etc.) is performed as necessary. The obtained toothpaste can be placed in a container to make a product. The shape and material of the container are not particularly limited, and containers used for conventional toothpaste compositions can be used, such as containers such as laminated tubes made of plastics such as polyethylene, polypropylene, polyethylene terephthalate, and nylon.

[0056] In this embodiment, the oral composition preferably has a pH (25° C.) of 5.0 to 9.0. The pH can be adjusted by adding a pH adjuster, adjusting the component composition, and the like.

[0057] The viscosity of the oral composition of this embodiment can be adjusted appropriately depending on the dosage form, for example. When the oral composition is in paste or gel form, the viscosity at 25°C measured with a BH viscometer is preferably 30 to 150 Pa s.

[0058] In the case of an oral composition in a liquid dosage form, the viscosity at 25°C measured with a BH viscometer should be 30 mPa·s or less, and preferably 0.7 to 30 mPa·s. [Example]

[0059] The present invention will be described below with reference to examples, which are not intended to limit the scope of the present invention.

[0060] [Materials used in the Examples and Comparative Examples] -Component (A) Cationic disinfectant- Chlorhexidine hydrochloride (Fujifilm Wako Pure Chemical Industries, Ltd.) Cetylpyridinium chloride (cetylpyridinium chloride, Fujifilm Wako Pure Chemical Industries, Ltd.) Benzalkonium chloride (NissanCation (registered trademark) M2-100R, manufactured by NOF Corporation) Benzethonium chloride (Hyamine 1622, manufactured by Lonza Japan)

[0061] -Component (B) Nonionic surfactant- POE sorbitan fatty acid ester (polyoxyethylene sorbitan monostearate (20E.O.), NIKKOL (registered trademark) TS-10V, manufactured by Nippon Surfactant Industry Co., Ltd.) Polyoxyethylene hydrogenated castor oil (20E.O.) (NIKKOL® HCO-20, manufactured by Nippon Surfactant Industries Co., Ltd.) Alkyl glucoside (C12-C16) (Plantacare 1200 UP, manufactured by BASF Japan)

[0062] -Component (C) Fluorine-containing compound- Sodium fluoride (Sodium fluoride, manufactured by Stella Chemifa Co., Ltd.) Sodium Monofluorophosphate (ICL Japan Co., Ltd.)

[0063] -Other ingredients- Silica anhydride (abrasive silica) (Zeodent 115, Evonik) Sorbitol solution (70%) (Mitsubishi Corporation Life Sciences) Xanthan gum (DSP Gokyo Food & Chemical Co., Ltd.) Sodium polyacrylate (manufactured by Toagosei Co., Ltd.) Propylene glycol (ADEKA) Saccharin sodium (Aisan Chemical Industry Co., Ltd.) Fragrances A to P (The composition of each fragrance is shown in Table 4.) purified water

[0064] <Manufacturing method of test sample> Test products (dentifrice compositions) having the formulations shown in Tables 1 to 3 below were produced by a standard method.

[0065] The resulting dentifrice compositions (Examples 1 to 14 and Comparative Examples 1 to 6) were evaluated according to the following procedures, and the evaluation results are shown in Tables 1 to 3 below.

[0066] <Evaluation of disinfecting power>

[0067] 50 g of each dentifrice composition was filled into three laminated tubes, and the tubes were stored at 50° C. for three months. The dentifrice compositions were then returned to room temperature and subjected to the following tests.

[0068] Forty microliters of frozen P. gingivalis culture was added to 4 mL of Todd-Hewitt Broth (Becton, Dickinson) culture medium (THBHM) containing 5 mg / L hemin (Sigma) and 1 mg / L vitamin K (Wako Pure Chemical Industries, Ltd.). After anaerobically culturing at 37°C for two nights (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen), the turbidity at 660 nm (OD660) was adjusted to 1 to prepare a bacterial suspension.

[0069] 40 mL of artificial saliva was added to 10 g of the dentifrice composition, stirred, and then centrifuged (10,000 rpm, 10 minutes). The resulting supernatant was used as the sample stock solution. 2 mL of this sample stock solution was allowed to act on 2 mL of bacterial solution for 30 seconds, and 50 μL was then removed and used as a sample solution for evaluating bactericidal activity. For the evaluation of bactericidal activity, the sample solution for evaluation (50 μL) was added to THB liquid medium (4 mL) and cultured (37°C, 8 hours), after which the amount of grown bacteria was measured using turbidity (OD660) as an index. Three tubes were evaluated in the same manner, and the smaller the average value, the higher the bactericidal activity obtained.

[0070] The artificial saliva used was prepared by dissolving 3.73 g of potassium chloride, 0.14 g of monopotassium dihydrogen phosphate, 0.15 g of calcium chloride dihydrate, and 0.02 g of magnesium chloride hexahydrate in purified water, adjusting the pH to 7 with potassium hydroxide, and making up to 1,000 mL.

[0071] <Criteria for determining bactericidal activity> ◎: OD660 is less than 1 ○: OD660 is 1 or more and less than 1.2 △: OD660 is 1.2 or more and less than 2 ×: OD660 is 2 or more

[0072] <Evaluation of the kneaded skin> 50 g of each dentifrice composition was filled into three laminated tubes and stored at -5°C for one month. At -5°C, three 15 cm tubes of the composition were dispensed onto an evaluation paper, and the evaluation paper was folded to slightly crush the composition. When the paper was opened to its original state, the kneaded surface of the composition was evaluated according to the following evaluation criteria 1. The three tubes were evaluated in the same manner, and the average score was evaluated according to evaluation criteria 2.

[0073] Scoring Criteria 1 5 points: No wrinkles or grains, the surface is shiny 4 points: Some wrinkles and no shine 3 points: There are some wrinkles or grains 2 points: Wrinkles and grains are uniformly observed 1 point: Many wrinkles and grains are uniformly observed, and the composition is not uniform

[0074] Evaluation Criteria 2 ◎: Average score 4.6 points or more ○: Average score 4.3 points or more and less than 4.6 points △: Average score 4.0 or more and less than 4.3 points ×: Average score less than 4.0 points

[0075] [Table 1]

[0076] [Table 2]

[0077] [Table 3]

[0078] [Table 4]

[0079] [Table 5]

[0080] [Table 6]

[0081] [Table 7]

[0082] Comparative Examples 1 and 2, which did not contain component (A) or component (B), Comparative Examples 3 and 4, in which the content of component (C) converted into fluoride ion concentration did not satisfy the range of 3,000 to 20,000 ppm, and Comparative Examples 5 and 6, in which the ratio (C) / (B) did not satisfy the range of 2,000 to 50,000, showed poor results in either the evaluation items of bactericidal power or smooth skin. In contrast, the dentifrice compositions of Examples 1 to 14, which contained components (A) to (C) and in which the content of component (C) and the ratio (C) / (B) satisfied the above numerical ranges, showed good results in either the evaluation items of bactericidal power and smooth skin. Furthermore, when the fragrance A used in the compositions of Examples 1 to 14 and Comparative Examples 1 to 6 was replaced with fragrances B to P, the evaluation results did not change.

[0083] Furthermore, the compositions of Examples 1 to 14 showed good results in an antibacterial activity evaluation using Porphyromonas gingivalis, a typical bacterium that causes periodontal disease, demonstrating that the oral compositions of the present invention are also useful in the treatment or prevention of periodontal diseases, including pyorrhea.

Claims

1. Component (A): cationic disinfectant, Component (B): a nonionic surfactant, and Component (C): Fluorine-containing compound Contains The content of component (C) is an amount equivalent to a fluorine ion concentration of 3,000 to 20,000 ppm, the ratio (C) / (B) of the fluorine ion concentration corresponding to the content of component (C) to the content of component (B) is 2,000 to 50,000; Oral composition.

2. 2. The oral composition according to claim 1, wherein component (A) is at least one selected from the group consisting of chlorhexidine hydrochloride, cetylpyridinium chloride, benzalkonium chloride, and benzethonium chloride.

3. 3. The oral composition according to claim 1, wherein component (B) is at least one member selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, and alkyl glucoside.

4. 3. The oral composition according to claim 1, wherein the content of component (B) is 0.05 to 10.0% by mass.

5. 4. The oral composition according to claim 3, wherein component (B) contains polyoxyethylene hydrogenated castor oil in an amount of 0.05 to 10% by mass based on the total amount of the composition.

6. 4. The oral composition according to claim 3, wherein component (B) contains 0.05 to 10% by mass of a polyoxyethylene sorbitan fatty acid ester relative to the total amount of the composition.

7. 4. The oral composition according to claim 3, wherein component (B) contains 0.05 to 10% by mass of alkyl glucoside based on the total amount of the composition.

8. 3. The oral composition according to claim 1, which is a dentifrice composition.

9. The oral composition according to claim 1 or 2, which is an external application composition.

10. 3. The oral composition according to claim 1, which is for treating or preventing periodontal disease.

11. Component (A): cationic disinfectant, Component (B): a nonionic surfactant, and Component (C): Fluorine-containing compound Contains The content of component (C) is an amount equivalent to a fluorine ion concentration of 3,000 to 20,000 ppm, the ratio (C) / (B) of the fluorine ion concentration corresponding to the content of component (C) to the content of component (B) is 2,000 to 50,000; A therapeutic or preventive agent for periodontal disease.